Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

Pevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies. Here we report the results of a phase I trial characterizing the mass balance, phar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaofei, Sedarati, Farhad, Faller, Douglas V., Zhao, Dan, Faessel, Hélène M., Chowdhury, Swapan, Bolleddula, Jayaprakasam, Li, Yuexian, Venkatakrishnan, Karthik, Papai, Zsuzsanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960626/
https://www.ncbi.nlm.nih.gov/pubmed/33089874
http://dx.doi.org/10.1007/s10637-020-01017-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960626/
https://www.ncbi.nlm.nih.gov/pubmed/33089874
http://dx.doi.org/10.1007/s10637-020-01017-x

Ejemplares similares